Tags : Immuno-Oncology Therapies


Gilead Signs an Agreement with Carna Biosciences to Develop and

Shots: Carna to receive $20M upfront, up to $450M as development & commercial milestones and royalties on sales. Gilead to get WW rights to develop and commercialize inhibitors against immuno-oncology target and an exclusive right to access Carna’s lipid kinase drug discovery platform The focus of the collaboration is to advance novel immunotherapies targeting cancer […]Read More